Medifast (NYSE:MED – Get Free Report) announced its earnings results on Monday. The specialty retailer reported $0.66 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.12), Briefing.com reports. The business had revenue of $174.74 million during the quarter, compared to the consensus estimate of $168.90 million. Medifast had a net margin of 7.55% and a return on equity of 36.64%. The company’s revenue was down 49.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.67 EPS. Medifast updated its Q2 guidance to $0.05-0.40 EPS and its Q2 2024 guidance to 0.050-0.400 EPS.
Medifast Stock Down 4.3 %
MED stock opened at $26.36 on Thursday. The company has a market cap of $288.32 million, a PE ratio of 4.25 and a beta of 1.19. The business has a 50-day simple moving average of $35.52 and a 200 day simple moving average of $53.93. Medifast has a 52 week low of $25.92 and a 52 week high of $109.52.
Insiders Place Their Bets
In other Medifast news, Director Scott Schlackman sold 4,053 shares of the business’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $39.44, for a total transaction of $159,850.32. Following the completion of the transaction, the director now owns 7,785 shares of the company’s stock, valued at $307,040.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 2.06% of the company’s stock.
Analyst Ratings Changes
Get Our Latest Research Report on Medifast
Medifast Company Profile
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
Featured Stories
- Five stocks we like better than Medifast
- How to Use the MarketBeat Excel Dividend Calculator
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- Consumer Staples Stocks, Explained
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- Trading Stocks: RSI and Why it’s Useful
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.